Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30544187 | 1.00 | CTBP2 (0.57) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL11834577 | 0.93 | CTBP2 (0.55) | CTBP2POLBL3MBTL1NPC1CACNA1G | |
| SCHEMBL4191880 | 0.85 | CTBP2 (0.44) | CTBP2ALDH1A1 | |
| SCHEMBL24458263 | 0.84 | CTBP2 (0.57) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL29635163 | 0.83 | CTBP2 (0.61) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL7073775 | 0.83 | CTBP2 (0.61) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL29407189 | 0.82 | CTBP2 (0.64) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL1259064 | 0.82 | CTBP2 (0.59) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL2532630 | 0.82 | CTBP2 (0.64) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL504093 | 0.82 | CTBP2 (0.64) | CTBP2POLBL3MBTL1NPC1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115448869-A | Preparation method of intermediate for synthesizing spirotetramat | 顺毅南通化工有限公司 | 2022-12-09 | — | — | CN | claimed |
| CN-115448869-B | Preparation method of intermediate for synthesizing spirotetramat | 顺毅南通化工有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-116715634-A | Compound, pharmaceutical composition and application thereof in preparation of vasodilation drugs | 山东第一医科大学(山东省医学科学院) | 2023-09-08 | — | — | CN | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| CN-115448869-A | Preparation method of intermediate for synthesizing spirotetramat | 顺毅南通化工有限公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021222789-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
| CN-108707114-B | Acetamide compound and preparation method and application thereof | 上海泰禾国际贸易有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-105130970-B | N- sulfonyl homoserine lactone analog derivative, preparation method and use | 中国人民解放军军事医学科学院毒物药物研究所 | 2019-06-25 | — | — | CN | disclosed |
| US-4197303-A | ANTIARRHYTHMIA AGENTS, ALKOXYCARBONYL ON 4-POSITION OF PIPERIDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-08 | — | — | US | disclosed |
| US-4197304-A | ANTIARRHYTHMIA AGENTS, N-PYRIDINYL-N-(4-ALKYLPIPERIDINYL)THIENYLACETAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-08 | — | — | US | disclosed |
| US-4196210-A | ANTIARRHYTHMIA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-01 | — | — | US | disclosed |
| US-4182764-A | DIURETIC, URICOSURIC | MERCK & CO., INC. (US) | 1980-01-08 | — | — | US | disclosed |
| US-4177285-A | DIURETICS, HYPOTENSIVES | MERCK & CO., INC. (US) | 1979-12-04 | — | — | US | disclosed |
| US-4157393-A | ANTIARRHYTHMIA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-06-05 | — | — | US | disclosed |
| US-4151286-A | ANTIARRHYTHMIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-04-24 | — | — | US | disclosed |
| US-4126689-A | ANTIARRHYTHMIA | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-11-21 | — | — | US | disclosed |
| US-4096267-A | (1-Oxo-2-aryl or thienyl-2-substituted-5-indanyloxy (or thio) alkanoic acids, and derivatives thereof | MERCK & CO., INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-3984552-A | 6-Oxo-7-substituted and 7,7-disubstituted-6H-indeno-[5,4-b]furan (and thiophene) carboxylic acids | MERCK & CO., INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | CTBP2 850/4885POLB 2643/4885L3MBTL1 1336/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | CTBP2 850/4885POLB 2643/4885L3MBTL1 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.